Cerity Partners
VIR icon

Cerity Partners’s Vir Biotechnology VIR Stock Holding History

Cerity Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Sell
32,634
-3,230
-9% -$30.7K ﹤0.01% 2723
2026
Q1 		$321K Buy
35,864
+19,775
+123% +$158K ﹤0.01% 2564
2025
Q4 		$97K Sell
16,089
-1,738
-10% -$10.3K ﹤0.01% 2751
2025
Q3 		$102K Sell
17,827
-16,076
-47% -$82.2K ﹤0.01% 2625
2025
Q2 		$171K Buy
33,903
+18,882
+126% +$101K ﹤0.01% 2394
2025
Q1 		$97.3K Buy
+15,021
New +$134K ﹤0.01% 2325
2024
Q4 		– Sell
-16,435
Closed -$123K – 2606
2024
Q3 		$123K Buy
+16,435
New +$143K ﹤0.01% 2406
2024
Q2 		– Sell
-11,642
Closed -$118K – 2416
2024
Q1 		$118K Buy
+11,642
New +$119K ﹤0.01% 2186

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cerity Partners's VIR Position: Q2 2026 in Review

Cerity Partners reduced its Vir Biotechnology (VIR) stake by 9% in Q2 2026, selling an estimated $30.7K and leaving 32,634 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

Cerity Partners first reported a position in VIR in Q1 2024 and has held it in 8 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Cerity Partners held 32,634 shares of Vir Biotechnology worth $333K as of Q2 2026.
  • Cerity Partners sold 3,230 Vir Biotechnology shares in Q2 2026, an estimated $30.7K.
  • Vir Biotechnology made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2723 holding.
  • Cerity Partners first reported a position in Vir Biotechnology in Q1 2024 and has held it in 8 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.